ANAPC11

Across TCGA pan-cancer cohorts, ANAPC11 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANAPC11 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANAPC11 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANAPC11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where ANAPC11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.940	0.679	.001	33	view →
LUAD	DFS	Quartile	All	0.823	0.980	.004	32	view →
LSCC	DFS	Median	All	0.899	0.493	.018	5	view →
UCEC	DFS	Median	III,IV	1.000	0.343	.027	4	view →
GBM	OS	Median	All	0.634	0.378	.026	4	view →
HNSC	DFS	Quartile	IV	1.000	0.457	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANAPC11–CCRCC (OS)

Open the CCRCC breakdown →